will be removed from its pipeline. In July, H.C. Wainwright initiated coverage of AnaptysBio (NASDAQ:ANAB) with a buy rating ...

Stocks surged on Friday, with the S&P 500 soaring 2.13% as investors welcomed a break from tariff-driven turmoil. The market ...

ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns.

indicating expedited progress in the company's clinical development pipeline. AnaptysBio announced an exclusive global license agreement with Vanda Pharmaceuticals for imsidolimab, which includes ...

Shares of AnaptysBio, Inc. ANAB, a clinical-stage biotechnology company, plunged 32.8% on Dec. 11 after it announced that the phase IIb study of pipeline candidate, ANB032, a BTLA agonist ...

https://www.tipranks.com/news/the-fly/medtronic-price-target-raised-to-93-from-89-at-truist Truist notes that AnaptysBio (ANAB) reported the “much anticipated ...

Ratings for AnaptysBio ANAB were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below ...

Has AnaptysBio, Inc. (ANAB) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

In other AnaptysBio news, Director Ecor1 Capital, Llc bought 6,646 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was acquired at an average price of $12.95 ...

Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on ANAB: AnaptysBio NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Explore AnaptysBio stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for ANAB. UiPath Posts Weak Revenue, Joins SentinelOne, American Eagle And Other Big ...